Table 1. Summary of clinical information from 6 HBV/HIV-1 coinfected and 14 HBV mono-infected patients.
| Variable | HBV Mono-infected | HBV/HIV-1 Coinfected |
|---|---|---|
| Sex N = M/F | 14 = 13M/1F a | 6 = 5M/1F |
| Median Age, years (range) | 46.2 (26–62) | 45 (22–60) |
| HBeAg Positive, N | 7/14 | 3/6 |
| Median HBV DNA, IU/mL (range) b | Baseline: 5.4 x 105 (<20–3.6 x 107); Follow up: 3.6 x 102 (<10–1.7 x 103) | 313 (<55–690) |
| Median alanine aminotransferase (IU/L) (range) | 47.5 (23–236) | 43 (15–54) |
| Median CD4+ T cell (cells/mm3) (range) | N/A c | 240 (114–800) |
| Median HIV RNA, copies/mL (range) d | N/A | <40 (<40–104) |
| Liver Fibrosis Stage by Transient Elastography, N | Stage 0–1 (N = 8), Stage 2 (N = 4), Stage 3–4 (N = 2) | Unknown |
| Antiviral Treatment | 14/14 baseline Rx naïve, 1/5 follow up Rx naïve, 4/5 follow up on anti-HBV Rx | 5/6 on HAART with anti-HBV activity e |
a 5/14 follow-up samples (4/5 on therapy).
b HBV DNA tested using kinetic PCR (sensitivity <20 or <55 IU/mL, 100–300 copies/mL; TaqMan, Roche).
c normal CD4+ T cell count is 500 cells/mm3 to 1,000 cells/mm3.
d HIV RNA tested using real time PCR assay with sensitivity <40 or 75–1010 virus copies/mL (Abbott m2000).
e HAART—highly active antiretroviral therapy.